Valuation: Immuneering Corporation

Market Cap 338M 290M 272M 248M 468M 32.26B 473M 3.2B 1.25B 16.27B 1.27B 1.24B 53.9B P/E 2026 *
-4.7x
P/E 2027 * -4.05x
Enterprise Value 338M 290M 272M 248M 468M 32.26B 473M 3.2B 1.25B 16.27B 1.27B 1.24B 53.9B EV / Sales 2026 *
-
EV / Sales 2027 * 19.8x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day+0.97%
1 week+3.98%
Current month+26.63%
1 month+21.06%
3 months-2.97%
6 months-0.19%
Current year-20.52%
1 week 5.12
Extreme 5.125
5.43
1 month 4.03
Extreme 4.03
5.43
Current year 3.86
Extreme 3.86
8.48
1 year 3.86
Extreme 3.86
10.08
3 years 1
Extreme 1
10.08
5 years 1
Extreme 1
33.25
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 01/02/2008
Director of Finance/CFO 61 16/07/2026
Chief Tech/Sci/R&D Officer - 01/08/2023
Director TitleAgeSince
Chairman 81 01/01/2008
Director/Board Member 44 01/02/2008
Director/Board Member 72 27/04/2021
Date Insider Type Main position Quantity % Market Cap.
7/16/26 A Other

Chief Financial Officer

225,000 0.3478%
7/16/26 A Free

Chief Financial Officer

650,000 1.0047%
2/3/26 A Free

Chief Technology Officer

140,000 0.2168%
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%+3.98%-12.10%-44.60% 338M
+3.31%-3.70%+61.03%+103.64% 71.35B
+1.74%+1.06%+49.02%+87.38% 64.17B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-3.07%+5.85%+55.43%+12.04% 27.33B
+3.98%+4.37%+39.47%-14.65% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
+0.19%+0.48%+8.32%+545.40% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
Average +1.36%+4.41%+52.53%+173.17% 28.87B
Weighted average by Cap. +1.61%+3.32%+55.47%+154.59%

Financials

2026 *2027 *
Net sales - 17.06M 14.62M 13.7M 12.51M 23.62M 1.63B 23.85M 162M 62.91M 821M 64.07M 62.67M 2.72B
Net income -74.1M -63.5M -59.5M -54.35M -103M -7.06B -104M -702M -273M -3.56B -278M -272M -11.8B -85.92M -73.62M -68.99M -63.02M -119M -8.19B -120M -814M -317M -4.13B -323M -316M -13.69B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
57
Date Price Change Volume
25/08/26 $5.230 +0.97% 364,300
24/08/26 $5.180 -2.26% 400,571
21/08/26 $5.300 +0.95% 445,715
20/08/26 $5.250 -1.50% 473,164
19/08/26 $5.330 +5.96% 751,062
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.230USD
Average target price
17.57USD
Spread / Average Target
+235.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock